|
 The European Medicines Agency's human medicines committee has
started a "rolling review" of Moderna's mRNA-1273 vaccine candidate
and is evaluating the first batch of data, the regulator said.
Rolling reviews allow drug companies to submit applications for
COVID-19 medicinal products before development work is concluded and
prior to the availability of complete supporting documentation,
aimed at speeding up any approval process.
In October, Moderna had said it would apply for real-time reviews of
its vaccine in Europe.
[to top of second column] |
EMA's announcement comes a week after Switzerland began a real-time review of
data from Moderna's vaccine candidate.
Moderna said earlier this month that it has enough data for a first interim
analysis of its late-stage COVID-19 vaccine trial.
(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Sriraj Kalluvila)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
